http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 07:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Strategic+Expansion+of+Bucillamine+Program+Across+Infectious+Diseases%2C+Defence+and+Biothreat+Medical+Countermeasures/26524904.html <p><i><strong>Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling</strong></i></p> <p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 20, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, today announced its strategic expansion plan for bucillamine across infectious disease, defence and biothreat-related applications.</p><p>Revive believes bucillamine represents a differentiated strategic asset with potential relevance across multiple high-need areas, including infectious diseases, future pandemic http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Strategic+Expansion+of+Bucillamine+Program+Across+Infectious+Diseases%2C+Defence+and+Biothreat+Medical+Countermeasures/26524904.html Wed, 20 May 2026 07:45:00 -0400 RVVTF http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+Announces+Strategic+Expansion+of+Bucillamine+Program+Across+Infectious+Diseases%2C+Defence+and+Biothreat+Medical+Countermeasures/26524904.html <p><i><strong>Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling</strong></i></p> <p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 20, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, today announced its strategic expansion plan for bucillamine across infectious disease, defence and biothreat-related applications.</p><p>Revive believes bucillamine represents a differentiated strategic asset with potential relevance across multiple high-need areas, including infectious diseases, future pandemic http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+Announces+Strategic+Expansion+of+Bucillamine+Program+Across+Infectious+Diseases%2C+Defence+and+Biothreat+Medical+Countermeasures/26524904.html Wed, 20 May 2026 07:45:00 -0400 RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Strengthens+Bucillamine+IP+Portfolio+with+North+American+Patent+Filings+for+Nerve+Agent+Exposure+and+Granted+Canadian+Patent+for+Infectious+Diseases/26142619.html <p><i><strong>Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications</strong></i></p><p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 11, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, is pleased to announce two important intellectual property milestones for bucillamine: (i) the filing of the U.S. and Canadian national phase patent applications under <strong>PCT/CA2024/000008</strong> for <strong>"Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent,"</strong> and (ii) the grant http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Strengthens+Bucillamine+IP+Portfolio+with+North+American+Patent+Filings+for+Nerve+Agent+Exposure+and+Granted+Canadian+Patent+for+Infectious+Diseases/26142619.html Wed, 11 Mar 2026 07:30:00 -0400 RVVTF http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+Strengthens+Bucillamine+IP+Portfolio+with+North+American+Patent+Filings+for+Nerve+Agent+Exposure+and+Granted+Canadian+Patent+for+Infectious+Diseases/26142619.html <p><i><strong>Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications</strong></i></p><p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 11, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, is pleased to announce two important intellectual property milestones for bucillamine: (i) the filing of the U.S. and Canadian national phase patent applications under <strong>PCT/CA2024/000008</strong> for <strong>"Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent,"</strong> and (ii) the grant http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+Strengthens+Bucillamine+IP+Portfolio+with+North+American+Patent+Filings+for+Nerve+Agent+Exposure+and+Granted+Canadian+Patent+for+Infectious+Diseases/26142619.html Wed, 11 Mar 2026 07:30:00 -0400 RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF